Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
HER2-тестирование методами иммуногистохимии, флуоресцентной (FISH) и хромогенной (SISH) in situ гибридизации при раке желудка и пищеводно-желудочного перехода
HER2-тестирование методами иммуногистохимии, флуоресцентной (FISH) и хромогенной (SISH) in situ гибридизации при раке желудка и пищеводно-желудочного перехода
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Статья посвящена анализу различных методов определения HER2-статуса распространенного рака желудка. На собственном материале проведено сравнение различных антител, использующихся при тестировании, и различных вариантов выявления амплификации гена HER2. Даны рекомендации по использованию предлагаемых методов.
Ключевые слова: HER2, рак желудка, иммуногистохимия, in situ гибридизация.
Key words: HER2, gastric cancer, immunohistochemistry, in situ hybridization.
Ключевые слова: HER2, рак желудка, иммуногистохимия, in situ гибридизация.
________________________________________________
Key words: HER2, gastric cancer, immunohistochemistry, in situ hybridization.
Полный текст
Список литературы
1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden. Globocan 2000. Int J Cancer 2001; 94: 153–6.
2. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathologica et Microbiologica Scandinavica 1965; 64: 31–49.
3. Souza RF, Spechler SJ. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin 2005; 55: 334–51.
4. Давыдов М.И., Тер-Ованесов М.Д. Рак проксимального отдела желудка: современная классификация, тактика хирургического лечения, факторы прогноза РМЖ. Онкология. 2008; 16 (13): 914–21.
5. Курс лекций по патологической анатомии. Частный курс. Ч. II (1, 2). Под ред. акад. РАН и РАМН, проф. М.А.Пальцева. М.: Русский врач, 2003.
6. Murad AM, Santiago FF, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37–41.
7. Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648–57.
8. Ajani JA, Rodriguez W, Bodoky G et al. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS). J Clin Oncol 2000; 27. Abstr. 8.
9. Popesku NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989; 4 (3): 362–6.
10. Slamon DJ, Leyland-Jones B et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER-2. New England J Medicine 2001; 344 (11): 783–92.
11. Moelans CB, van Diest PJ, Milne AN. Offerhaus GJA HER-2/neu testing and therapy in gastroesophageal adenocarcinoma. Pathology Research International 2011.
12. Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathol 2008; 52: 797–805.
13. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathol 2011; 58 (3): 383–94.
14. García-García E, Gómez-Martín C, Angulo B et al. Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. Histopathol 2011; 59 (1): 8–17.
15. Tanner M, Hollmen M, Juntilla T et al. Amplification of HER2 in gastric carcinoma: association with Topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann of Oncol 2005; 16 (2): 273–8.
16. Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J National Cancer Institute 2009; 101 (19): 1306–7.
17. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann of Oncol 2008; 19 (9): 1523–9.
18. Barros-Silva JD, Leitão D, Afonso L, Vieira J et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Brit J Cancer 2009; 100 (3): 487–93.
19. Kim MA, Jung EJ, Lee HS et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007; 38: 1386–93.
20. Park DI, Yun JW, Park JH et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371–9.
21. Takehana T, Kunitomo K, Kono K et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002; 98: 833–7.
2. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathologica et Microbiologica Scandinavica 1965; 64: 31–49.
3. Souza RF, Spechler SJ. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin 2005; 55: 334–51.
4. Давыдов М.И., Тер-Ованесов М.Д. Рак проксимального отдела желудка: современная классификация, тактика хирургического лечения, факторы прогноза РМЖ. Онкология. 2008; 16 (13): 914–21.
5. Курс лекций по патологической анатомии. Частный курс. Ч. II (1, 2). Под ред. акад. РАН и РАМН, проф. М.А.Пальцева. М.: Русский врач, 2003.
6. Murad AM, Santiago FF, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37–41.
7. Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648–57.
8. Ajani JA, Rodriguez W, Bodoky G et al. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS). J Clin Oncol 2000; 27. Abstr. 8.
9. Popesku NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989; 4 (3): 362–6.
10. Slamon DJ, Leyland-Jones B et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER-2. New England J Medicine 2001; 344 (11): 783–92.
11. Moelans CB, van Diest PJ, Milne AN. Offerhaus GJA HER-2/neu testing and therapy in gastroesophageal adenocarcinoma. Pathology Research International 2011.
12. Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathol 2008; 52: 797–805.
13. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathol 2011; 58 (3): 383–94.
14. García-García E, Gómez-Martín C, Angulo B et al. Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. Histopathol 2011; 59 (1): 8–17.
15. Tanner M, Hollmen M, Juntilla T et al. Amplification of HER2 in gastric carcinoma: association with Topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann of Oncol 2005; 16 (2): 273–8.
16. Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J National Cancer Institute 2009; 101 (19): 1306–7.
17. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann of Oncol 2008; 19 (9): 1523–9.
18. Barros-Silva JD, Leitão D, Afonso L, Vieira J et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Brit J Cancer 2009; 100 (3): 487–93.
19. Kim MA, Jung EJ, Lee HS et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007; 38: 1386–93.
20. Park DI, Yun JW, Park JH et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371–9.
21. Takehana T, Kunitomo K, Kono K et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002; 98: 833–7.
Авторы
Л.Э.Завалишина, А.А.Рязанцева, Ю.Ю.Андреева, Г.А.Франк
ФГБУ Московский научно-исследовательский онкологический институт им. П.А.Герцена Минздравсоцразвития РФ, Москва
ФГБУ Московский научно-исследовательский онкологический институт им. П.А.Герцена Минздравсоцразвития РФ, Москва
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.